We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+60.76%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$323M
AUM Growth
+$81M
Cap. Flow
+$51.5M
Cap. Flow %
15.94%
Top 10 Hldgs %
43.73%
Holding
97
New
25
Increased
29
Reduced
18
Closed
15

Top Buys

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$15M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$10.5M
3
KRYS icon
Krystal Biotech
KRYS
+$8.67M
4
BIIB icon
Biogen
BIIB
+$4.63M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$4.59M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$7.2M
2
NUVL
Nuvalent
NUVL
+$6.29M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.11M
4
PHVS icon
Pharvaris
PHVS
+$3.48M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$2.94M

Sector Composition

Rank Sector Weight
1 Healthcare 91.53%
2 Consumer Staples 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELOX
76
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$210K 0.07%
54,075
– –
PVLA
77
Palvella Therapeutics
PVLA
$2.05B
$159K 0.05%
+12,017
New +$729K
EVGN icon
78
Evogene
EVGN
$5.83M
$107K 0.03%
+10,000
New +$67.6K
GKOS icon
79
Glaukos
GKOS
$9.49B
$71.2K 0.02%
+1,000
New +$57.4K
VRAY
80
DELISTED
ViewRay, Inc.
VRAY
$35.2K 0.01%
100,000
-2,693,748
-96% -$2.79M
RCKTW icon
81
Rocket Pharmaceuticals Warrant
RCKTW
$320K
$19.9K 0.01%
104,828
– –
FRTX
82
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$7.01K ﹤0.01%
10,000
– –
ABOS icon
83
Acumen Pharmaceuticals
ABOS
$152M
– –
-146,922
Closed -$597K
ALNY icon
84
Alnylam Pharmaceuticals
ALNY
$38.3B
– –
-14,043
Closed -$2.81M
ALT icon
85
CALL
Altimmune
ALT
$568M
– –
-415,700
Closed -$1.75M
ATXS
86
DELISTED
Astria Therapeutics
ATXS
– –
-93,823
Closed -$1.25M
CGEM icon
87
Cullinan Oncology
CGEM
$1.06B
– –
-265,032
Closed -$2.71M
CVRX icon
88
CVRx
CVRX
$131M
– –
-30,000
Closed -$280K
ETNB
89
CALL
DELISTED
89bio
ETNB
– –
-200,000
Closed -$3.05M
LVTX
90
DELISTED
LAVA Therapeutics
LVTX
– –
-140,291
Closed -$233K
MCRB icon
91
Seres Therapeutics
MCRB
$45M
– –
-11,626
Closed -$1.32M
MDGL icon
92
Madrigal Pharmaceuticals
MDGL
$12.6B
– –
-10,000
Closed -$2.42M
PLRX icon
93
CALL
Pliant Therapeutics
PLRX
$65M
– –
-199,600
Closed -$5.31M
REGN icon
94
Regeneron Pharmaceuticals
REGN
$72.9B
– –
-5,000
Closed -$4.11M
IMGN
95
CALL
DELISTED
Immunogen Inc
IMGN
– –
-1,128,200
Closed -$4.33M
BLU
96
DELISTED
BELLUS Health Inc.
BLU
– –
-1,000,000
Closed -$7.2M
RXDX
97
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-13,921
Closed -$1.49M
1 2 3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM

Silverarc Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Silverarc Capital Management held 97 positions worth $323M, up 33% from $242M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Silverarc Capital Management deployed $51.5M of net new capital in Q2 2023, opening 25 new positions and adding to 29 existing holdings. Its largest new stake was Mirati Therapeutics, Inc. Common Stock: 91,213 shares worth $3.3M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 88% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Nuvalent, an estimated $6.29M trimmed.

  • Silverarc Capital Management's largest Q2 2023 buy was Mirati Therapeutics, Inc. Common Stock: 91,213 shares worth $3.3M.
  • Silverarc Capital Management added most to Immunogen Inc in Q2 2023, an estimated $15M increase.
  • Silverarc Capital Management's biggest Q2 2023 reduction was Nuvalent, cutting an estimated $6.29M.
  • Silverarc Capital Management fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $7.2M.
  • Silverarc Capital Management's ten largest holdings make up 44% of its $323M portfolio in Q2 2023.
  • Silverarc Capital Management opened 25 new positions and closed 15 in Q2 2023.
  • Silverarc Capital Management's portfolio value rose 33% quarter-over-quarter to $323M.

Based on Silverarc Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.